suscept
lung
injuri
individu
predisposit
abnorm
lung
function
polygen
risk
gene
current
identifi
poor
socioeconom
statu
chronic
asthma
fetal
growth
retard
poor
nourish
histori
pulmonari
tuberculosi
risk
factor
copd
acut
exacerb
copd
aecopd
produc
signific
morbid
mortal
risk
factor
includ
viral
bacteri
infect
chang
environment
condit
smog
gastroesophag
reflux
lack
complianc
mainten
treatment
sever
baselin
diseas
histori
prior
exacerb
season
demonstr
aecopd
occur
northern
southern
latitud
approxim
two
time
frequent
winter
summer
aecopd
respons
greatest
proport
health
carerel
cost
associ
copd
discuss
chapter
focu
impact
aecopd
diseas
cours
infecti
caus
aecopd
treatment
well
prevent
option
patient
copd
usual
present
progress
short
breath
cough
sputum
product
symptom
associ
acceler
declin
lung
function
may
continu
despit
smoke
cessat
dyspnea
usual
start
exercis
occur
minim
exert
rest
diseas
progress
cough
sputum
product
usual
intermitt
pronounc
morn
chronic
pulmonari
diseas
similar
clinic
present
acut
exacerb
differenti
copd
treatment
differ
exampl
includ
asthma
cystic
fibrosi
bronchiectasi
diffus
panbronchiol
oblit
bronchiol
worsen
symptom
increas
sputum
volum
transit
sputum
color
clear
green
yellow
suggest
acut
exacerb
commonli
occur
winter
main
differenti
diagnosi
exacerb
patient
copd
includ
pneumonia
congest
heart
failur
common
comorbid
patient
chronic
lung
diseas
irrevers
airflow
limit
reduc
forc
expiratori
volum
second
fev
fev
forc
vital
capac
fvc
ratio
acut
exacerb
indic
acut
chang
patient
baselin
increas
dyspnea
sputum
volum
sputum
purul
number
chang
clinic
defin
sever
preval
expect
reach
overal
popul
smoker
fourth
lead
caus
death
worldwid
increas
risk
acut
exacerb
winter
risk
factor
cigarett
smoke
environment
particul
matter
genet
predisposit
intermitt
progress
airway
inflamm
remodel
loss
lung
function
ciliari
dysfunct
excess
mucu
product
impair
phagocytosi
lead
bacteri
colon
airway
patient
stabl
diseas
frequent
colon
streptococcu
pneumonia
haemophilu
influenza
moraxella
catarrhali
respiratori
syncyti
viru
frequent
colon
viru
microaspir
stabl
diseas
introduc
oral
anaerob
eg
prevotella
veillonella
spp
lower
airway
acut
exacerb
bacteria
virus
may
isol
gramneg
rod
found
worsen
lung
function
atyp
bacteria
frequent
isol
acquisit
new
pathogen
associ
exacerb
acut
exacerb
defin
increas
sputum
purul
volum
dyspnea
use
bronchodil
increas
mild
exacerb
without
antibiot
therapi
oral
intraven
administ
corticosteroid
earli
empir
antibiot
therapi
advis
moder
sever
exacerb
avoid
exposur
particul
matter
ceas
smoke
administ
influenza
pneumococc
pertussi
vaccin
prescrib
prophylact
daili
azithromycin
patient
advanc
diseas
histori
exacerb
cardiac
risk
factor
keyword
acut
exacerb
copd
aecopd
azithromycin
bronchiti
bronchodil
chronic
obstruct
pulmonari
diseas
copd
corticosteroid
use
copd
gold
copd
summari
haemophilu
lung
inflamm
lung
microbiom
microbiom
moraxella
streptococcu
pneumonia
therapi
copd
exacerb
vaccin
outpati
set
presenc
high
sever
prompt
consider
hospit
admiss
clinic
sign
risk
respiratori
failur
import
measur
current
exacerb
sever
tachypnea
especi
respiratori
rate
breath
min
tachycardia
inabl
speak
full
sentenc
fatigu
indic
hospit
oxygen
satur
mislead
hypoxemia
frequent
late
event
progress
respiratori
failur
acut
symptomat
patient
arteri
blood
ga
analysi
use
oximetri
diagnos
hypercapnia
well
hypoxemia
use
accessori
muscl
paradox
breath
character
inward
motion
abdomen
inspir
indic
diaphragmat
fatigu
impend
respiratori
failur
abdomin
paradox
breath
progress
hypercapnia
deterior
mental
statu
usual
indic
need
ventilatori
support
intens
care
unit
noninvas
invas
positivepressur
ventil
addit
diagnost
test
includ
chest
radiographi
identifi
pulmonari
infiltr
electrocardiographi
assess
cardiac
ischemia
arrhythmia
particularli
paroxysm
atrial
tachycardia
basic
metabol
panel
help
assess
sever
aecopd
elev
level
sodium
bicarbon
sign
chronic
hypercapnia
increas
anion
gap
sign
anaerob
metabol
respiratori
muscl
sepsi
syndrom
hyponatremia
sometim
occur
result
syndrom
inappropri
secret
antidiuret
hormon
hyperglycemia
respons
stress
system
corticosteroid
renal
insuffici
manifest
reduc
cardiac
output
endstag
pulmonari
hypertens
presenc
derang
may
warrant
hospit
although
chest
radiographi
insensit
test
diagnos
copd
usual
first
step
evalu
patient
progress
dyspnea
cough
use
assess
symptomat
patient
advanc
lung
cancer
pulmonari
fibrosi
congest
heart
failur
sometim
copd
suspect
chest
radiograph
show
hyperinfl
flatten
diaphragm
increas
retrostern
space
bulla
observ
copd
highli
like
ct
imag
modal
choic
evalu
copd
mani
symptomat
pulmonari
diseas
data
suggest
quantit
ct
allow
estim
risk
exacerb
frequenc
determin
indic
diseas
impact
bode
pathophysiolog
impair
lung
function
copd
caus
destruct
remodel
larg
small
airway
due
chronic
inflamm
caus
complex
interact
ambient
toxic
inhal
chang
microbiom
airway
mucosa
host
immun
respons
inflammatori
chang
lung
function
deterior
becom
promin
exacerb
fig
earli
patholog
produc
inflamm
bronchiol
less
mm
diamet
follow
parenchym
remodel
earli
stage
central
airway
wall
infiltr
lymphocyt
produc
bronchial
wall
thicken
evidenc
chest
ct
apoptosi
necrosi
epitheli
endotheli
cell
also
present
activ
cell
diseas
progress
neutrophil
becom
promin
releas
neutrophil
elastas
lead
parenchym
destruct
persist
airway
injuri
also
produc
squamou
metaplasia
loss
cilia
function
affect
bronchial
segment
diseas
larg
small
airway
contribut
airflow
obstruct
ventil
heterogen
pulmonari
hypertens
due
loss
pulmonari
capillari
bed
also
develop
copd
chronic
hypoxia
also
produc
vasoconstrict
lead
fix
structur
chang
worsen
pulmonari
hypertens
diseas
progress
frequent
exacerb
copd
contribut
increas
lung
inflamm
persist
loss
lung
function
mucos
inflamm
copd
patient
increas
alveolar
macrophag
alveoli
bronchiol
small
airway
alveolar
macrophag
major
sourc
inflammatori
cytokin
growth
factor
recruit
inflammatori
cell
lung
acceler
diagnosi
copd
character
progress
airflow
obstruct
defin
reduct
forc
expiratori
volum
second
fev
low
ratio
fev
forc
vital
capac
fvc
pulmonari
function
test
chronic
bronchiti
emphysema
two
major
clinic
subtyp
overlap
common
treatment
similar
littl
clinic
import
distinguish
chronic
bronchiti
emphysema
chronic
bronchiti
defin
histori
product
cough
month
per
year
least
success
year
emphysema
use
patholog
diagnosi
distal
airspac
enlarg
accompani
destruct
alveolar
wall
modern
era
highresolut
comput
tomographi
ct
abl
defin
extent
distribut
emphysema
increas
use
ct
screen
lung
cancer
asymptomat
smoker
diagnos
emphysema
sever
stabl
copd
base
pulmonari
function
tabl
initi
result
standard
pulmonari
function
test
normal
abnorm
earli
diseas
may
requir
sensit
techniqu
evalu
distal
lung
function
impuls
oscillometri
progress
patient
suffer
decreas
fev
decreas
fev
fvc
ratio
increas
total
lung
capac
caus
air
trap
expir
alveolar
destruct
promot
airway
collaps
reduc
diffus
capac
carbon
monoxid
dlco
lung
eventu
sever
airflow
obstruct
lead
abnorm
arteri
blood
gase
hypoventil
pco
mm
hg
hypoxemia
po
mmhg
integr
physiolog
paramet
symptom
use
valid
predictor
mortal
one
commonli
use
composit
criteria
accur
character
copd
call
bode
includ
bodymass
index
airflow
obstruct
defin
abnorm
fev
dyspnea
exercis
capac
evalu
walk
test
bode
predict
respons
rehabilit
hospit
mortal
although
univers
agreement
defin
diagnos
aecopd
commonli
defin
acut
event
worsen
respiratori
symptom
beyond
normal
daytoday
variat
usual
requir
increas
rescu
inhal
use
control
symptom
one
wide
use
scale
diagnos
presenc
sever
aecopd
requir
patient
least
one
follow
clinic
present
upper
respiratori
tract
infect
symptom
within
previou
day
increas
wheez
fever
without
anoth
identifi
caus
increas
heart
rate
respiratori
rate
greater
baselin
scale
categor
patient
three
group
base
whether
worsen
dyspnea
increas
sputum
purul
andor
increas
sputum
volum
sever
exacerb
three
criteria
moder
exacerb
two
mild
exacerb
one
risk
factor
associ
copd
exacerb
includ
three
copd
exacerb
previou
year
reduc
fev
smoke
nonadher
oxygen
therapi
risk
sever
exacerb
depend
patient
medic
histori
includ
baselin
fev
number
prior
exacerb
prior
need
mechan
ventil
comorbid
wherea
vast
major
aecopd
manag
viciou
cycl
could
explain
associ
poor
oral
health
increas
airway
bacteri
load
copd
exacerb
reduc
lung
function
virus
bacteria
lower
airway
perpetu
inflamm
copd
caus
damag
number
mechan
may
ciliotox
invad
epitheli
cell
caus
apoptosi
increas
mucin
product
degrad
humor
immun
via
secret
iga
proteas
bacteri
molecul
endotoxin
membran
lipoprotein
peptidoglycan
fragment
lipoteicho
acid
activ
innat
immun
respons
exacerb
inflamm
copd
patient
whose
airway
heavili
colon
bacteria
higher
concentr
inflammatori
cytokin
neutrophil
respiratori
secret
high
bacteri
burden
lower
airway
associ
acceler
fev
declin
comorbid
exacerb
wors
symptom
exacerb
stabl
copd
rate
posit
routin
bacteri
cultur
sputum
vari
howev
interpret
sputum
cultur
difficult
owe
upper
airway
contamin
reduc
specif
failur
grow
fastidi
bacteria
complex
lower
airway
microbiom
reduc
sensit
stabl
copd
nonpotenti
pathogen
microorgan
isol
much
frequent
potenti
pathogen
microorgan
nonpotenti
pathogen
microorgan
usual
oropharyng
microb
corynebacterium
spp
neisseria
spp
enterococcu
spp
coagulaseneg
staphylococci
streptococcu
viridan
fungi
candida
spp
commonli
isol
potenti
pathogen
microorgan
streptococcu
pneumonia
haemophilu
influenza
moraxella
catarrhali
cultureindepend
technolog
assay
microbi
nucleic
acid
antigen
often
found
potenti
pathogen
cultureneg
respiratori
specimen
exampl
one
third
stabl
copd
patient
haemophilu
influenza
within
airway
epitheli
cell
alveolar
macrophag
highthroughput
sequenc
microbi
rrna
gene
yield
rel
unbias
estim
rel
abund
uncultiv
cultiv
bacteria
lower
airway
normal
individu
harbor
low
level
oral
bacteria
prevotella
spp
veillonella
spp
cultureindepend
techniqu
challeng
dogma
lower
airway
normal
steril
provid
evid
viciou
inflammatori
cycl
produc
microaspir
spite
increas
number
alveolar
macrophag
impair
phagocytosi
reduc
abil
clear
bacteria
lower
airway
therebi
caus
inflamm
oxid
stress
neutrophil
also
recruit
activ
nonresolv
pulmonari
inflamm
particularli
exacerb
neutrophil
elastas
metalloproteinas
lead
lung
parenchyma
destruct
neutrophil
elastas
also
potent
mucou
secretagogu
lead
mucou
gland
hyperplasia
neutrophil
short
tissu
life
span
airway
neutrophilia
observ
copd
requir
continu
neutrophil
recruit
smoke
also
impair
neutrophil
phagocyt
function
collectin
pentraxin
complement
also
defici
impair
mucos
immun
predispos
lower
respiratori
tract
infect
pulmonari
inflamm
continu
smoke
cessat
part
owe
perman
structur
damag
part
owe
recoveri
proinflammatori
capac
epitheli
cell
bacteri
colon
lower
airway
also
import
determin
degre
airway
system
inflamm
stabl
copd
inflammatori
mediat
spill
produc
system
inflamm
elev
level
creactiv
protein
crp
fibrinogen
leukocyt
count
elev
crp
level
strongli
associ
ischem
heart
diseas
smoker
system
comorbid
vascular
diseas
major
risk
factor
mortal
copd
exacerb
system
inflamm
caus
copd
also
hypothes
associ
anemia
osteoporosi
depress
metabol
syndrom
microb
stabl
copd
increas
bacteri
colon
lower
airway
copd
occur
owe
chronic
microaspir
impair
clearanc
bacteria
frequent
copd
exacerb
copd
patient
frequent
microaspir
owe
gastroesophag
reflux
due
incoordin
breath
swallow
impair
mucociliari
clearanc
smoker
reduc
abil
clear
oral
microb
lower
airway
exacerb
inflamm
lead
chronic
cough
progress
incoordin
breath
swallow
inhal
medic
may
also
carri
oral
bacteria
lower
airway
bacteri
burden
sputum
eosinophil
greater
lung
function
impair
longer
hospit
like
virus
bacteria
induc
independ
inflammatori
pathway
account
sever
present
poorer
outcom
patient
coinfect
treatment
stabl
copd
improv
patient
symptom
function
statu
reduc
risk
exacerb
slow
declin
lung
function
smoke
cessat
avoid
environment
exposur
import
intervent
prevent
diseas
progress
encourag
everi
medic
visit
multipl
differ
behavior
pharmacolog
treatment
explor
includ
vareniclin
nicotin
replac
bupropion
pneumococc
influenza
combin
tetanu
diphtheriaacellular
pertussi
tdap
vaccin
also
recommend
everi
copd
patient
agonist
anticholinerg
bronchodil
usual
longact
formul
mainstay
symptom
control
tabl
drug
relax
airway
smooth
muscl
produc
bronchodil
also
antiinflammatori
activ
although
clinic
signific
clear
anticholinerg
medic
also
reduc
sputum
product
patient
chronic
bronchiti
corticosteroid
steadyst
copd
restrict
adjunct
therapi
complement
longact
bronchodil
sever
case
residenti
organ
especi
individu
alreadi
damag
lung
oral
anaerob
like
modul
pulmonari
immun
respons
health
diseas
possibl
support
grow
bodi
data
link
periodont
copd
exacerb
reduc
lung
function
howev
technic
challeng
produc
contamin
lower
airway
sampl
upper
airway
secret
need
resolv
better
understand
role
airway
microbiom
copd
pathogenesi
respiratori
virus
also
frequent
found
patient
stabl
copd
use
cultur
polymeras
chain
reaction
pcr
techniqu
assess
sputum
common
respiratori
viru
respiratori
syncyti
viru
rsv
found
copd
patient
follow
nonrsv
virus
rhinoviru
coronaviru
parainfluenza
viru
sampl
increas
inflamm
also
report
adenoviru
highthroughput
complementari
dna
sequenc
identifi
viral
transcript
unbias
approach
fuller
understand
role
virom
stabl
copd
aecopd
await
resolut
technic
challeng
highcoverag
rna
sequenc
lower
respiratori
tract
sampl
two
third
patient
copd
exacerb
bacteria
virus
cultur
lower
airway
secret
aerob
bacteria
isol
half
patient
respiratori
virus
isol
one
third
bacterialvir
coinfect
present
fourth
patient
acut
exacerb
increas
incid
aecopd
winter
may
reflect
signific
role
virus
play
pathogenesi
aecopd
h
influenza
pneumonia
catarrhali
bacteri
pathogen
commonli
isol
copd
exacerb
three
also
colon
stabl
copd
patient
higher
bacteri
load
associ
aecopd
seri
studi
use
molecular
biolog
techniqu
sethi
associ
observ
acquisit
new
bacteri
strain
preced
aecopd
increas
total
bacteri
load
copd
exacerb
rel
small
compar
total
bacteri
load
model
humor
cellular
immun
respons
new
bacteri
viral
strain
like
drive
increas
inflamm
caus
copd
exacerb
individu
greater
degre
function
impair
recent
antibiot
use
system
corticosteroid
therapi
higher
rate
isol
gramneg
bacteria
pseudomona
aeruginosa
stenotrophomona
maltophilia
member
enterobacteriacea
sputum
patient
fev
greater
predict
valu
system
corticosteroid
antibiot
within
preced
month
low
probabl
enterobacteriacea
p
aeruginosa
sputum
cultur
h
influenza
p
aeruginosa
common
patient
poorer
lung
function
polymicrobi
exacerb
occur
advanc
pulmonari
dysfunct
sever
exacerb
role
atyp
bacteri
pathogen
mycoplasma
pneumonia
chlamydia
pneumonia
legionella
pneumophila
exacerb
poorli
defin
rare
found
aecopd
variat
report
rate
atyp
pathogen
could
relat
technic
geograph
differ
report
serolog
pneumonia
antigen
detect
use
indic
presenc
pneumonia
pathogen
pcr
assay
cultur
frequent
confirm
presenc
altern
two
report
itali
greec
demonstr
pneumonia
among
patient
aecopd
use
serolog
pcr
techniqu
controversi
also
exist
regard
role
c
pneumonia
copd
exacerb
sever
wellconduct
studi
detect
c
pneumonia
l
pneumophila
wherea
other
detect
c
pneumonia
aecopd
chronic
colon
c
pneumonia
occur
one
third
patient
associ
wors
pulmonari
function
one
studi
unlik
stabl
copd
rhinoviru
viru
frequent
associ
aecopd
coronaviru
parainfluenza
adenoviru
influenza
viru
human
metapneumoviru
also
occur
less
preval
coinfect
virus
bacteria
produc
higher
vs
increas
median
time
next
exacerb
day
placebo
group
day
receiv
antibiot
studi
publish
sinc
recent
metaanalysi
suggest
antibiot
may
benefici
patient
mild
moder
aecopd
sever
studi
demonstr
delay
time
relaps
exacerb
use
antibiot
treat
aecopd
retrospect
cohort
outpati
studi
patientvisit
relaps
defin
return
visit
within
day
antibiot
reduc
relaps
rate
compar
among
patient
receiv
antibiot
patient
receiv
amoxicillin
howev
even
higher
relaps
rate
compar
receiv
antibiot
anoth
studi
antibiot
ad
oral
corticosteroid
increas
median
time
second
third
exacerb
day
day
reduc
mortal
limit
effect
antibiot
less
sever
exacerb
may
result
lower
bacteri
burden
healthier
group
patient
given
larg
number
patient
copd
develop
aecopd
potenti
econom
impact
term
antibiot
cost
toxic
treatment
much
effort
identifi
patient
requir
antibiot
recent
welldesign
clinic
investig
use
procalcitonin
biomark
bacteri
infect
acut
exacerb
attempt
limit
unnecessari
antibiot
use
reduc
emerg
antibiot
resist
c
difficil
infect
author
gold
guidelin
recommend
antibiot
therapi
patient
aecopd
meet
one
follow
criteria
present
three
cardin
symptom
increas
dyspnea
increas
sputum
volum
increas
sputum
purul
present
two
cardin
symptom
increas
purul
sputum
one
two
symptom
sever
exacerb
requir
mechan
ventil
invas
noninvas
recent
studi
patient
meet
criteria
frequent
prescrib
antibiot
studi
involv
outpati
inpati
demonstr
although
approxim
patient
receiv
antibiot
purul
sputum
found
among
patient
studi
unit
state
correl
use
antibiot
presenc
indic
use
recent
studi
patient
meet
gold
criteria
antibiot
receiv
antibiot
hospit
wherea
approxim
met
criteria
receiv
antibiot
although
use
bacteri
cultur
treatment
aecopd
debat
use
purul
defin
need
antibiot
base
sever
studi
demonstr
relationship
sputum
color
andor
neutrophil
posit
bacteri
cultur
sputum
purul
excel
guid
antibiot
use
sever
studi
one
sputum
purul
present
antibiot
withheld
patient
fail
therapi
anoth
studi
purul
use
determin
whether
antibiot
would
prescrib
therapeut
failur
rate
among
nonpurul
sputum
receiv
antibiot
versu
among
purul
sputum
receiv
antibiot
clear
mani
patient
prescrib
antibiot
need
current
state
knowledg
clearli
defin
group
harm
help
cours
antibiot
gold
recommend
use
antibiot
base
symptom
particular
sputum
purul
remain
best
guid
decid
patient
aecopd
requir
antibiot
recent
compar
studi
employ
noninferior
design
demonstr
equival
antibiot
among
commonli
studi
antibiot
macrolid
azithromycin
clarithromycin
secondgener
cephalosporin
cefuroxim
cefpodoxim
cefdinir
penicillinpenicillinas
inhibitor
ampicillin
clavulan
quinolon
ciprofloxacin
levofloxacin
moxifloxacin
gemifloxacin
trimethoprimsulfamethoxazol
tetracyclin
doxycyclin
trial
perform
among
copd
inhal
corticosteroid
reduc
mortal
reduc
copd
exacerb
decreas
inflamm
stabil
lung
function
moder
sever
copd
unfortun
inhal
corticosteroid
increas
risk
pneumonia
must
balanc
benefit
less
frequent
exacerb
drug
nonselect
select
phosphodiesteras
inhibitor
eg
theophyllin
roflumilast
respect
may
also
consid
patient
sever
copd
frequent
exacerb
adequ
control
longact
bronchodil
system
corticosteroid
either
oral
intraven
bronchodil
inhal
agonist
without
anticholinerg
cornerston
pharmacolog
treatment
aecopd
shortact
bronchodil
prefer
allow
titrat
dose
requir
clinic
trial
evalu
use
longact
bronchodil
aecopd
although
sicker
patient
nebul
bronchodil
routin
use
hospit
data
suggest
similar
bronchodil
effect
metereddos
inhal
cours
system
corticosteroid
reduc
treatment
failur
inpati
outpati
manag
copd
exacerb
system
corticosteroid
prefer
exacerb
reduc
recoveri
time
improv
lung
function
increas
arteri
oxygen
system
corticosteroid
also
reduc
rate
earli
relaps
length
hospit
stay
although
data
support
specif
dose
rout
administr
corticosteroid
global
initi
chronic
obstruct
lung
diseas
gold
guidelin
recommend
mg
oral
prednisolon
per
day
day
earli
antibiot
treatment
aecopd
outpati
inpati
set
becom
nearli
routin
clinic
practic
even
though
role
bacteria
mani
case
aecopd
uncertain
choic
antibiot
chang
past
sever
decad
part
reflect
chang
resist
pattern
infect
bacteria
well
avail
newer
antibiot
taken
less
frequent
improv
antimicrobi
activ
less
toxic
studi
evalu
effect
antibiot
treatment
mostli
small
difficult
compar
heterogen
patient
popul
divers
outcom
measur
vari
definit
failur
addit
mani
differ
antibiot
treatment
durat
evalu
reduc
compar
individu
studi
two
recent
metaanalys
cochran
review
conclud
antibiot
improv
outcom
aecopd
among
inpati
especi
requir
admiss
intens
care
unit
among
hospit
patient
antibiot
reduc
hospit
mortal
antibiot
also
led
improv
peak
expiratori
flow
largest
studi
date
evalu
antibiot
efficaci
retrospect
cohort
inpati
acut
care
center
unit
state
administr
antibiot
within
first
hour
reduc
need
mechan
ventil
hospit
day
vs
lower
rate
inpati
mortal
vs
reduc
readmiss
vs
produc
fewer
treatment
failur
vs
howev
higher
rate
clostridium
difficil
patient
treat
antibiot
vs
weight
evid
support
antibiot
use
hospit
patient
particularli
admit
intens
care
unit
oppos
rel
highqual
evid
support
use
antibiot
inpati
set
less
convinc
evid
recommend
antibiot
outpati
cochran
review
cite
earlier
reduct
treatment
failur
found
analyz
outpati
studi
found
analysi
restrict
studi
use
current
avail
antibiot
howev
recent
multicent
doubleblind
placebocontrol
clinic
trial
mild
moder
aecopd
document
amoxicillinclavulan
improv
respons
therapi
within
day
macrolid
cohort
antimicrobi
recommend
larger
group
copd
patient
acut
exacerb
extrapol
data
fig
treatment
empir
base
risk
factor
antibiot
resist
infect
enterobacteriacea
p
aeruginosa
extent
depend
need
hospit
see
fig
specif
choic
antibiot
made
understand
local
bacteri
resist
pattern
toxic
allergi
drug
interact
comorbid
sputum
sampl
recommend
routin
either
gold
guidelin
american
colleg
physiciansamerican
societi
intern
medicin
american
colleg
chest
physician
sputum
cultur
gram
stain
reliabl
term
indic
infect
pathogen
furthermor
earli
sputum
cultur
seem
affect
outcom
antibiot
treatment
among
inpati
except
patient
acut
exacerb
chronic
bronchiti
sever
metaanalys
perform
evalu
random
control
antibiot
comparison
trial
treatment
aecopd
agent
class
consist
superior
comparison
other
use
clinic
endpoint
although
singl
studi
one
agent
may
appear
superior
term
microbiolog
erad
one
bacterium
overal
microbiolog
erad
may
higher
relaps
rate
aecopd
treat
amoxicillin
compar
antibiot
increas
product
pneumonia
h
influenza
catarrhali
challeng
use
amoxicillin
ampicillin
firstlin
treatment
aecopd
evalu
patient
treat
either
quinolon
antibiot
patient
macrolid
antibiot
patient
taken
larger
retrospect
cohort
studi
hospit
patient
aecopd
show
similar
rate
treatment
success
although
less
diarrhea
clarithromycin
azithromycin
wide
studi
prophylact
agent
observ
placebocontrol
trial
suggest
longterm
macrolid
prophylaxi
effect
reduc
exacerb
hospit
recent
largescal
random
placebocontrol
studi
azithromycin
mg
daili
year
reduc
aecopd
exacerb
per
patientyear
placebo
group
exacerb
per
patientyear
azithromycin
group
antibiot
treatment
also
extend
time
first
exacerb
day
improv
qualiti
life
azithromycin
group
howev
hear
loss
among
patient
becam
colon
macrolid
resist
occur
treat
group
versu
placebo
control
group
importantli
trial
exclud
patient
cardiovascular
risk
includ
rest
heart
rate
greater
beat
per
minut
prolong
qt
qtc
interv
medic
increas
qtc
interv
therefor
potenti
advers
cardiac
reaction
report
macrolid
minim
studi
controversi
still
exist
increas
risk
cardiovascular
event
report
azithromycin
use
addit
intermitt
short
cours
macrolid
produc
fourfold
increas
pneumonia
within
month
mechan
reduc
exacerb
go
beyond
antibacteri
effect
drug
directli
antiinflammatori
decreas
proinflammatori
cytokin
product
adhes
molecul
reactiv
oxygen
speci
longterm
macrolid
also
studi
patient
cystic
fibrosi
bronchiectasi
led
fewer
exacerb
diseas
stabil
lung
function
patient
low
cardiovascular
risk
frequent
exacerb
spite
adequ
routin
therapi
macrolid
consid
see
tabl
howev
widespread
use
macrolid
less
sever
copd
case
current
recommend
anoth
strategi
prevent
aecopd
intermitt
antibiot
therapi
moxifloxacin
mg
day
everi
week
total
cours
reduc
odd
exacerb
intentiontotreat
analysi
among
patient
baselin
purul
sputum
author
report
increas
resist
moxifloxacin
among
cultur
bacteria
find
gastrointestin
problem
moxifloxacin
vs
placebo
research
need
confirm
benefit
approach
outweigh
risk
resist
c
difficil
coliti
strategi
gain
widespread
use
influenza
pneumococcu
tetanusdiphtheriaacellular
pertussi
tdap
vaccin
recommend
patient
copd
influenza
vaccin
recommend
annual
person
copd
center
diseas
control
prevent
cdc
advisori
committe
immun
practic
acip
observ
studi
demonstr
decreas
hospit
mortal
among
elderli
individu
receiv
influenza
vaccin
howev
data
random
placebocontrol
studi
less
compel
influenza
vaccin
significantli
reduc
aecopd
effect
fail
demonstr
signific
reduct
hospit
mortal
effect
influenza
vaccin
relat
age
sex
sever
copd
comorbid
ill
despit
result
placebocontrol
studi
given
lack
major
toxic
recommend
patient
copd
pneumococc
vaccin
also
recommend
person
copd
pneumococcu
common
colon
organ
well
pathogen
popul
observ
studi
demonstr
decreas
pneumococc
bacteremia
elderli
well
hospit
pneumonia
mortal
among
elderli
patient
chronic
lung
diseas
other
abl
corrobor
find
random
placebocontrol
trial
frequent
found
pneumococc
vaccin
effect
recent
metaanalysi
includ
seven
studi
two
use
vaccin
five
vaccin
author
report
reduct
likelihood
develop
pneumonia
prevent
aecopd
among
patient
receiv
vaccin
compar
analys
cochran
review
demonstr
decreas
allcaus
mortal
death
cardiorespiratori
caus
publish
data
recommend
consid
patient
fail
prior
therapi
patient
high
risk
infect
due
enterobacteriacea
p
aeruginosa
patient
aecopd
gener
present
signific
system
ill
definit
chest
radiograph
demonstr
new
pulmonari
infiltr
confus
creat
one
fifth
patient
hospit
communityacquir
pneumonia
normal
chest
film
hospit
admiss
develop
infiltr
within
hour
combin
overlap
aecopd
communityacquir
pneumonia
along
antibiot
resist
lead
frequent
use
broadspectrum
antibiot
mani
hospit
patient
aecopd
chest
radiograph
demonstr
infiltr
hour
antibiot
tailor
stop
still
may
use
aecopd
meet
criteria
despit
increas
resist
mani
older
antibiot
patient
still
respond
clinic
trimethoprimsulfamethoxazol
ciprofloxacin
equal
effect
recent
doubleblind
trial
among
patient
sever
aecopd
requir
mechan
ventil
surprisingli
bacteri
suscept
predict
clinic
success
may
due
poor
sensit
specif
sputum
sampl
defin
bacteria
caus
acut
exacerb
altern
aecopd
may
driven
chang
complex
lower
airway
microbiom
singl
microorgan
shift
lung
microbiom
could
produc
flare
inflamm
given
polymicrobi
natur
microbiom
organ
may
need
effect
treat
reduc
inflamm
near
futur
unbias
cultureindepend
techniqu
accur
describ
lung
microbiom
copd
better
understand
microbiom
chang
preced
aecopd
alter
produc
antibiot
improv
understand
antibiot
respons
outpati
studi
compar
durat
therapi
acut
exacerb
chronic
bronchiti
five
day
therapi
quinolon
secondgener
cephalosporin
macrolid
efficaci
associ
fewer
advers
reaction
day
antimicrobi
therapi
although
compar
inpati
trial
durat
therapi
vari
day
day
treatment
use
recent
studi
hospit
patient
aecopd
toler
oral
therapi
effect
intraven
antibiot
eight
day
therapi
current
recommend
ventilatorassoci
pneumonia
may
suffic
even
critic
ill
patient
therapi
viral
infect
patient
copd
would
consid
high
risk
sever
influenza
infect
offer
neuraminidas
inhibitor
eg
oseltamivir
zanamivir
present
influenzalik
ill
influenza
season
even
set
neg
rapid
viru
detect
studi
nonimmun
peopl
copd
close
famili
contact
person
influenza
receiv
chemoprophylaxi
neuraminidas
inhibitor
although
numer
virus
influenza
viru
associ
aecopd
note
earlier
current
treatment
option
virus
although
inhal
ribavirin
use
therapeut
infant
transplant
patient
sever
rsv
infect
studi
avail
use
agent
patient
copd
diagnost
therapeut
modal
improv
specif
antivir
therapi
may
becom
part
armamentarium
decreas
durat
copd
exacerb
bacteri
colon
lower
airway
play
signific
role
aecopd
prophylact
use
antibiot
investig
success
use
prolong
continu
oxytetracyclin
small
number
patient
attempt
great
britain
earli
effect
prophylaxi
oxytetracyclin
corrobor
later
studi
recent
erythromycin
demonstr
better
outcom
influenza
vaccin
pneumococc
vaccin
administ
compar
influenza
vaccin
alon
although
studi
regard
efficaci
tdap
among
patient
copd
serolog
diagnosi
switzerland
report
bordetella
pertussi
signific
portion
patient
aecopd
howev
cultur
pcr
assay
bordetella
spp
neg
studi
therefor
certain
interpret
serolog
data
tdap
recommend
cdc
acip
adult
age
year
patient
copd
receiv
vaccin
particularli
light
recent
surg
case
pertussi
report
among
adult
regard
use
conjug
vaccin
provid
better
coverag
recent
studi
demonstr
decreas
hospit
rate
introduct
pneumococc
vaccin
mark
young
elderli
although
present
age
group
although
may
hold
true
patient
histori
copd
data
stratifi
patient
underli
diseas
risk
factor
sever
studi
report
addit
effect
use
influenza
vaccin
pneumococc
vaccin
among
patient
copd
signific
reduct
hospit
well
mortal
vaccin
administ
compar
vaccin
two
recent
cohort
studi
japan
complet
refer
list
avail
onlin
expert
consult
